Mustang Bio
Mustang Bio develops next-generation cell and gene therapies aimed at treating hematologic cancers, glioblastoma, and rare genetic diseases. The company operates a state-of-the-art manufacturing facility in Worcester, MA, and collaborates with leading academic institutions to advance their therapeutic candidates.
Company Overview
Mustang Bio develops next-generation cell and gene therapies. The company focuses on translating medical breakthroughs into potential cures for hematologic cancers, glioblastoma, and rare genetic diseases. They are committed to providing first-in-class cell and gene therapies to patients with genetic diseases and aggressive forms of cancer.
Manufacturing Facility
Mustang Bio operates a manufacturing facility in Worcester, MA, which includes a fully equipped QC lab, full research and product development lab, and four separate cleanrooms. This facility, known as the Mustang Advanced Research Site (MARS), enhances their ability to manufacture high-quality therapies. The company invested $2.5 million in a 6,000 square-foot expansion, bolstering their manufacturing capabilities.
Clinical Therapy Programs
Mustang Bio has in-licensed clinical CAR T programs, including MB-106 for B-cell Non-Hodgkin Lymphoma and MB-101 for glioblastoma (GBM). Additionally, they are developing C134 (or MB-108), a next-generation oncolytic herpes simplex virus for glioblastoma multiforme, and MB-109, which combines MB-101 CAR T cell therapy with MB-108 oncolytic virus. They conduct robust clinical trials, with six ongoing trials to evaluate the efficacy of their therapies.
Collaborations and Strategic Growth
Mustang Bio collaborates with leading academic institutions, such as City of Hope and Mayo Clinic, to advance their cell and gene therapy programs. The company employs a strategic growth approach through targeted product acquisition, in-licensing, and co-development opportunities. These collaborations help Mustang Bio deliver next-generation therapies more effectively.
Proprietary CAR T Manufacturing
Mustang Bio focuses on CAR T cell therapy, which involves modifying patients' T-cells to recognize specific cancers. They have developed a proprietary CAR T manufacturing process and facility capable of processing therapies with unrivaled quality for both clinical development and commercialization. This ensures the production of high-quality therapies for patients with various types of cancer.